Proven Results with ILARIS

ILARIS® is the first and only once-monthly injection that is FDA approved for the treatment of Hyperimmunoglobulin D Syndrome / Mevalonate Kinase Deficiency (HIDS/MKD). This FDA approval was based on research that included 181 children and adults with Periodic Fever Syndromes.

ILARIS helps provide fast and sustained symptom relief

In a clinical study, patients with HIDS/MKD were given ILARIS and evaluated for a complete response. A complete response meant that at day 15 and throughout the entire 16-week treatment period, they had minimal or no disease activity.

Study participants were assessed for their CRP* measurements and given a Physician's Global Assessment (PGA) score. The PGA is a 5-point scale used to evaluate the overall disease severity of a patient.

*CRP: C-reactive protein is a blood test to measure inflammation in the body.

Each patient's PGA score was based on several signs and symptoms, including:

Abdominal and/or Stomach Pain

Abdominal and/or Stomach Pain

Canker Sores

Canker Sores

Swollen Lymph Nodes

Swollen Lymph Nodes

The following percentage of people with HIDS/MKD achieved a complete response just 15 days after their first dose of ILARIS, and did not experience a worsening of symptoms throughout the entire 16-week treatment period.

0%

35.1% of HIDS/MKD patients had minimal or no disease activity just 15 days after their first dose of ILARIS
35.1% of HIDS/MKD patients had minimal or no disease activity just 15 days after their first dose of ILARIS

35.1% of HIDS/MKD patients had minimal or no disease activity at Day 15 through Week 16 of the study.
(n=13/37)

35.1% of HIDS/MKD patients had minimal or no disease activity at Day 15 through Week 16 of the study.

(n=13/37)

Talk to a doctor about whether ILARIS may be right for your child.

Next: Safety Considerations